Healthcare Professionals
We value the expertise and commitment of healthcare providers and support them in finding new ways to help patients.
We value the expertise and commitment of healthcare providers and support them in finding new ways to help patients.
We are applying our scientific leadership in the kallikrein-kinin system and oral drug discovery to develop oral protease inhibitor medicines for patients with diseases caused by the proteases plasma kallikrein and Factor XIIa.
KalVista is focused on developing new oral treatments for HAE.
We’re committed to more than just developing new treatments; we’re dedicated to understanding every aspect of the patient journey. We invite healthcare professionals to explore Mind The HAE Attack where real patient stories and insights highlight the impact of on-demand treatment and importance of truly listening to those living with HAE.
To submit a medical inquiry, please visit www.kalvista.com/medinfo.
If you would like to speak with our Medical Information Department, please contact us at:
U.S.
+1 85K-ALV-ISTA (+1 855-258-4782)
Europe
UK: +44 800 066 8200
Ireland: +353 1800 851 333
France: +33 800 90 98 58
Switzerland: +41 800 080 100
Germany: +49 800 183 0525
Spain: +34 900 752 177
Italy: +39 800 931 452
–
For more information on the policy for KalVista Expanded Access.
Expanded Access to
Investigational medicines
–
We invite you to submit a proposal for external research requests, including investigator-initiated studies and collaborative research.
EXTERNAL RESEARCH
SUBMISSION FORM
–
We will evaluate medical education grant requests that are independent of commercial bias and are non-promotional in nature. Medical education grants can be requested to support a variety of different activities, including live events, web-based education, and enduring materials.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)